Reviving Investor Confidence in mRNA by Proving Clinical Value Beyond Vaccines & Building De-Risked Development Plans
- Identifying the clinical and strategic proof points investors expect before committing capital especially in oncology and rare disease
- Learning how to differentiate from vaccine legacy perception and position your platform for long-term, non-pandemic relevance
- Understanding the importance of having a clear development and reimbursement roadmap from day one, not post-funding